Related Party Transactions

9 Months Ended

Sep. 30, 2024

Related Party Transactions [Abstract]

Related Party Transactions

5.Related Party Transactions

Joint Venture regarding Eden BioCell

On December 18, 2018, the Company launched Eden BioCell, Ltd., or Eden BioCell, as a 50/50 joint venture with a company affiliated with the Chair of the Company's board of directors at that time, or Partner. Eden BioCell was formed to lead commercialization of the Company’s Sleeping Beauty-generated CAR-T therapies in the People’s Republic of China (including Macau and Hong Kong), Taiwan and Korea. The Company licensed to Eden BioCell the rights in Greater China for its third-generation Sleeping Beauty-generated CAR-T therapies targeting the CD19 antigen. The Partner contributed $10.0 million to Eden BioCell and has committed up to an additional $25.0 million to this joint venture. The Partner also managed all clinical development in the territory pursuant to a master services agreement between with Eden BioCell.

In September 2021, the Partner and Alaunos mutually agreed to dissolve the Eden BioCell joint venture. The joint venture agreement has been terminated and the Eden BioCell entity has been dissolved as of July 2023.

Collaboration with Dune Lake Capital

In January 2023, the Company entered into a consulting agreement with Dune Lake Capital, LLC, or Dune Lake Capital, which was founded by Dale Curtis Hogue, Jr., the Company's interim Chief Executive Officer. During the three and nine months ended September 30, 2023, the Company recorded expenses of approximately $12 and $37, respectively, for consulting services performed by Dune Lake Capital. The Company did not incur expenses to Dune Lake Capital during the three and nine months ended September 30, 2024.